Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials

The study evaluated the long-term efficacy of ritlecitinib 50 mg in adolescents with alopecia areata over a period of up to 3 years, involving 27 participants aged 12-17 years. Results showed that at 3 years, 84.6% of observed participants and 48.2% using last observation carried forward (LOCF) had a Severity of Alopecia Tool (SALT) score of ≤20. Additionally, 76.9% of observed participants and 40.7% using LOCF achieved a SALT score of ≤10. The Patients’ Global Impression of Change (PGI-C) indicated that 100% of observed participants and 73.1% using LOCF reported moderate or great improvement. Eyebrow and eyelash assessments also showed positive responses. The study concludes that ritlecitinib demonstrates long-term efficacy in treating alopecia areata in adolescents, although the decreasing number of participants over time limits data interpretation. The study was funded by Pfizer Inc.